Plattsburgh,
NY, USA -- Monaghan Medical Corporation announced its AEROBIKA®
Oscillating Positive Expiratory Pressure (OPEP) device
has received a 2017 Innovative Technology designation from Vizient,
Inc., the largest member-driven health care
performance improvement company in the country. The designation was
based on direct feedback from hospital experts who interacted with
the AEROBIKA® OPEP device at the Vizient Innovative Technology
Exchange in Denver on Sept. 14, 2017.
The
AEROBIKA® OPEP device is a drug-free, handheld mechanical
oscillating positive expiratory pressure (OPEP) device that has been
designed to address the structural and functional challenges in the
airways of patients with COPD. When the patient exhales through the
device, it helps to expand the airways, loosen and expel mucus from
the lungs and may also enhance drug deposition. It has been shown to
improve lung function, exercise capacity and quality of life in COPD
patients,1 and a real-world study showed that the device reduced
exacerbation rates in patients during the critical 30-day
post-exacerbation period.2 These improved outcomes (equivalent to 6
fewer exacerbations per 100 patients per year) equate to a cost
savings of $553 per patient with the AEROBIKA® OPEP device compared
with no OPEP/PEP use, making the device a cost-effective treatment
for COPD patients.
"We
are extremely pleased to have been awarded this prestigious
recognition from Vizient," said Dominic Coppolo, MBA, RRT,
FAARC, Vice President Clinical Strategy and Development. "Our
device was recommended by Vizient members, which is a validation of
all of the design and clinical work we have done to support our
customers. We are the only OPEP device to have received this
designation at this year's Innovative Technology Exchange, and are
proud it was recognized to deliver improved outcomes and enhanced
safety."
"Based
on feedback from attendees at the Vizient Innovative Technology
Exchange, it was determined that the AEROBIKA® OPEP device should be
recognized with an Innovative Technology designation. This
designation will be noted in our online member contract catalog.
Congratulations to Monaghan Medical Corporation on receiving this
status," said Debbie Archer, director of procurement and Vizient
Innovative Technology Program lead.
Vizient
represents a diverse membership base that includes academic medical
centers, pediatric facilities, community hospitals, integrated health
delivery networks and non-acute health care providers and represents
more than $100 billion in annual purchasing volume. Through its
Innovative
Technology Program, Vizient works with member-led
councils and task forces to review potentially innovative products.
If it is determined that a product is innovative, Vizient may award a
contract outside of the competitive bid cycle.
About
Monaghan Medical Corporation (MMC, USA)
MMC
offers leading aerosol drug delivery devices and respiratory
management products including AeroEclipse® II BAN,
AeroChamber Plus® aVHC and the Aerobika®
device exclusively, directly and through distributors, in the United
States. MMC's strength lies in its commitment to product quality,
outcome based solutions for customers, and its collaboration with a
state-of-the-art aerosol research laboratory.
(http://www.monaghanmed.com)
1.
Svenningsen S, Paulin GA, Sheikh K, et al. Oscillatory Positive
Expiratory Pressure in Chronic Obstructive Pulmonary Disease. COPD.
2016;13(1):66-74.
2.
Burudpakdee C, Seetasith A, Dunne P, et al. A real-world study of
30-day exacerbation outcomes in chronic obstructive pulmonary disease
(COPD) patient managed with Aerobika OPEP. Pulmonary Therapeutics.
2017.
For
clinical inquiries, please contact:
Dominic
P. Coppolo, MBA, RRT, FAARC
Vice
President Clinical Strategy and Development
Monaghan
Medical Corporation
1-800-343-9071
